Omeprazol Xiromed (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Xiromed, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders in adults and children. GNH USA supplies Omeprazol Xiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Xiromed is a proton pump inhibitor that acts on gastric acid secretion pathways. - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal erosion. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition.

Adverse reactions to Omeprazol Xiromed vary in frequency and severity.

Common Side Effects: - Headache: mild and transient. - Diarrhea: usually self‑limiting. - Nausea: occasional mild discomfort. - Abdominal pain: mild cramping. - Flatulence: increased intestinal gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: kidney inflammation. - Stevens‑Johnson syndrome: severe skin reaction. - Hypersensitivity reactions: rash, angioedema, anaphylaxis. - Fracture risk: decreased bone mineral density with long‑term use.

When using Omeprazol Xiromed, consider the following safety measures: - Assess renal function: adjust use in severe renal impairment. - Review hepatic status: use cautiously in moderate liver disease. - Monitor long‑term therapy: evaluate need for continued treatment after 12 months. - Avoid unnecessary concomitant NSAID use: increased ulcer risk. - Counsel on symptom monitoring: report persistent abdominal pain or vomiting. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the plasma levels of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk. - Atazanavir: markedly decreased absorption, compromising HIV therapy. - Methotrexate (high dose): increased systemic exposure, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential INR elevation, requiring closer monitoring. - Phenytoin: possible reduction in serum levels, may need dose adjustment. - Digoxin: modest increase in concentration, monitor for toxicity.